Military-Tested PTSD App Wins FDA Clearance
the Psychiatry Advisor take:
The FDA has granted clearance on a mobile app that helps clinicians conduct cognitive tests on patients, which may be used to better diagnose post-traumatic stress disorder.
The app, known as DANA (Defense Automated Neurobehavioral Assessment), was developed by AnthroTronix and developed in part from funding from the Department of Defense. The technology has already been used in the field to evaluate service members deployed in Afghanistan.
DANA will be available as an app for both tablets and phone, and works with both Android and Apple iOS operating systems.
The company says the assessment DANA provides will be both cognitive and psychological. “The combination of these allows providers insight into the prevalence of symptoms related to both traumatic brain injuries and PTSD,” AnthroTronix said on its website.
Results DANA gathers “are evaluated by a qualified health professional who can assess factors that may affect measurement of reaction time such as concussion, dementia, post-traumatic stress, depression, stress, fatigue, prescription and non-prescription medications, and some nutritional supplements, among others,” the company told MobiHealthNews.
PTSD Mobile App Tested By Military Gets FDA Nod
Last week the FDA granted 510(k) clearance to a mobile-based cognitive test called DANA (Defense Automated Neurobehavioral Assessment), which helps healthcare providers better assess the medical or psychological state of their patients.
DANA was developed by Silver Spring, Maryland-based AnthroTronix, a digital health R&D company, and it was developed partially thanks to funding from the US Navy Bureau of Medicine and Surgery as well as a Rapid Innovation Fund award from the US Army.
The latter led to DANA being used to help evaluate the medical status, including possible post-traumatic stress disorder, of deployed military service members in Afghanistan.
Psychiatry Advisor Articles
- Etiology of Schizophrenia: Strong Association With Certain Rare Copy Number Variants
- Long-Term Lithium Use: More Evidence Needed to Associate With Cancer Risk
- FDA to Review Lumateperone for Treatment of Schizophrenia
- AMA Survey Collects Advice for Physicians Approaching Retirement
- Revised Children's Anxiety and Depression Scales Reliable Measurement Tool for Adults
- Cannabis Use, Cannabis Use Disorder Linked to Psychotic, Depressive Symptoms
- Abstinence From Regular Cannabis Use Improves Memory Among Adolescents, Young Adults
- Group Cognitive Behavioral Therapy Is Effective Treatment for Adolescent Anxiety
- Association Between Opioid and Benzodiazepine Misuse and Suicidal Ideation
- The Intersection of Eating and Alcohol Disorders: Detecting and Managing "Drunkorexia"
- Cognition, Depression, and Limited Functioning Linked in Middle Age
- Coping With Challenges When Working the Holidays
- Lithium Preferred Method of Maintenance Monotherapy in Older Adults With Bipolar Disorder
- Hypobetalipoproteinemia Associated With Aggression and Schizophrenia
- AMA Code of Medical Ethics Guides Physicians in Fighting Harmful Online Health Information